An Update to the Pilot Study of ¹⁷⁷Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer.

International family planning perspectives Pub Date : 2022-05-03 eCollection Date: 2022-01-01 DOI:10.3389/fnume.2022.863101

Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, Marcel J R Janssen, Steffie M B Peters, Willemijn A M van Gemert, Maike J M Uijen, Melline M G Schilham, J P Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O Barentsz, Winald R Gerritsen, J Alfred Witjes, James Nagarajah

{"title":"An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer.","authors":"Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, Marcel J R Janssen, Steffie M B Peters, Willemijn A M van Gemert, Maike J M Uijen, Melline M G Schilham, J P Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O Barentsz, Winald R Gerritsen, J Alfred Witjes, James Nagarajah","doi":"10.3389/fnume.2022.863101","DOIUrl":null,"url":null,"abstract":"177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.","PeriodicalId":81537,"journal":{"name":"International family planning perspectives","volume":"18 1","pages":"863101"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440840/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International family planning perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2022.863101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

¹⁷⁷Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of ¹⁷⁷Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, ¹⁷⁷Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.

查看原文本刊更多论文

177Lu-PSMA在低体积激素敏感性前列腺癌中的试点研究更新。

177Lu-PSMA-617放射性配体疗法是一种治疗终末期前列腺癌的新型疗法，也可用于前列腺特异性膜抗原（PSMA）高表达水平的激素敏感性前列腺癌患者。在这一视角中，我们回顾了177Lu-PSMA治疗低体积转移性激素敏感性前列腺癌患者的毒性、放射剂量和治疗效果的最新结果。此外，我们还介绍了参与该试验的患者的长期随访数据，如毒性和无雄激素剥夺疗法（ADT）的时间。总的来说，177Lu-PSMA 在这种情况下以及在长期随访中似乎是一种可行且安全的治疗方式。我们观察到，前列腺特异性抗原（PSA）反应超过 50%的男性似乎尤其能从这种疗法中获益，因为他们可以推迟 ADT，从而保持生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International family planning perspectives

自引率

0.00%

发文量